Aurigene Pharmaceutical Services Ltd., a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DNA encoded library (DEL) technologies, have partnered to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service.
COPENHAGEN, Denmark , April 4, 2022 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery agreement with Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target. Theseus will select hits for potential development into targeted tyrosine kinase inhibitors (TKIs) and will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.
COPENHAGEN, Denmark, Nov. 15, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with the allergy company ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected ALK protein targets. ALK will select hits for development into novel therapeutics for the prevention and treatment of a broad range of allergies. ALK will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.
COPENHAGEN, Denmark, Sept. 14, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with PhoreMost. Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost protein targets. PhoreMost will select hits for development into novel therapeutics for oncology. PhoreMost will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.